ArticleReviews in cardiovascular medicine2026
Sodium-Glucose Cotransporter 2 Inhibitors Shorten Echocardiography-Derived Total Atrial Conduction Time in Patients With Type 2 Diabetes Mellitus: A Prospective Pilot Study.
Article in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to improve cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). Structural and electrical atrial remodeling are among the myocardial alterations associated with diabetes. Total atrial conduction time (TACT), derived from echocardiography, serves as a marker of atrial remodeling. However, the effect of SGLT2i on TACT remains unclear. Methods: In this prospective, single-center pilot study, 130 patients with T2DM and preserved left ventricular ejection fraction were enrolled between March and December 2022. After excluding patients who discontinued therapy or met other exclusion criteria, 107 patients (57 treated with dapagliflozin and 50 with empagliflozin) were included in the analysis. Echocardiographic and laboratory evaluations were performed at baseline and six months after initiation of SGLT2i therapy. TACT was defined as the mean time between the onset of the P wave in lead II and the peak A' wave on tissue Doppler imaging (PA-TDI). Paired statistical tests, correlation analyses, and multiple linear regression were used to identify independent predictors of Δ TACT. Results: After six months of SGLT2i therapy, significant reductions were observed in blood pressure, lipid levels, glycated hemoglobin (HbA1c), and body mass index values (all Conclusions: SGLT2i therapy was associated with a significant reduction in TACT among T2DM patients, suggesting potential improvements in atrial remodeling and diastolic function. These findings support the hypothesis that the cardiovascular benefits of SGLT2i may extend to atrial conduction properties. Nonetheless, larger randomized studies are warranted to confirm these observations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.